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Background: Diabetes mellitus (DM) is associated with poor outcome after surgery. The prevalence of DM in
hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a patient with DM in the
operating room on a daily basis. Despite an abundance of published glucose lowering protocols and the known
negative outcomes associated with perioperative hyperglycaemia in DM, there is no evidence regarding the
optimal intraoperative glucose lowering treatment. In addition, protocol adherence is usually low and protocol
targets are not simply met.
Recently, incretins have been introduced to lower blood glucose. The main hormone of the incretin system is
glucagon-like peptide–1 (GLP-1). GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent
manner, resulting in glucose lowering action with a low incidence of hypoglycaemia.
We set out to determine the optimal intraoperative treatment algorithm to lower glucose in patients with DM type
2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus
regimen (BR) and GPL-1 (liragludite, LG) treatment.
Methods/Design: This is a multicentre randomised open label trial in patients with DM type 2 undergoing non-cardiac
surgery. Patients are randomly assigned to one of three study arms; intraoperative glucose-insulin-potassium infusion
(GIK), intraoperative sliding-scale insulin boluses (BR) or GPL-1 pre-treatment with liraglutide (LG). Capillary glucose
will be measured every hour. If necessary, in all study arms glucose will be adjusted with an intravenous bolus of
insulin. Researchers, care givers and patients will not be blinded for the assigned treatment. The main outcome
measure is the difference in median glucose between the three study arms at 1 hour postoperatively. We will include
315 patients, which gives us a 90% power to detect a 1 mmol l−1 difference in glucose between the study arms.
Discussion: The PILGRIM trial started in January 2014 and will provide relevant information on the perioperative use of
GLP-1 agonists and the optimal intraoperative treatment algorithm in patients with diabetes mellitus type 2.
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It is expected that the worldwide prevalence of diabetes
will increase from 220 million people now, to 300 million
people in 2025 [1]. Type 2 diabetes mellitus (DM) is most
common and accounts for 80% of the diabetic cases in
the Western World [2]. Because DM is accompanied by
macro- and microvascular complications, people with DM
are more likely to be admitted to the hospital than people
without DM. Twenty-two percent of in-hospital days are
occupied by patients with DM, who are especially over-
represented in the surgical population [3-5]. The preva-
lence of DM in hospitalised patients is up to 40% [3], thus
the anaesthesiologist will encounter a patient with DM in
the operating room on a daily basis.
Patients with DM have an increased risk of developing
hyperglycaemia during and after surgery. The glycaemic
control in the first 24 hours after surgery in patients
with DM is poor and associated with an increased risk
of postoperative infections [6-8]. In addition, hypergly-
caemia is associated with increased risk of postoperative
complications and length of hospital stay, irrespective of
the diagnosis of DM [9-13].
Considering the high prevalence of DM in the operating
theatre, the lack of evidence with regard to perioperative
glucose regulation in non-cardiac surgery patients with
DM is surprising. In contrast, stress hyperglycaemia in the
ICU or in cardiac surgery patients has been investigated in
a vast number of trials [14-16], but these studies did not
focus on DM [17].
For the perioperative glucose regulation multiple
protocols have been developed, ranging from intraven-
ous glucose-insulin-potassium infusion to subcutane-
ous sliding-scale insulin bolus regimens. Despite this
abundance of published glucose lowering protocols and
the proven negative associations of perioperative hypergly-
caemia in DM, there is no evidence to support an optimal
perioperative glucose lowering treatment. In addition, DM
protocol adherence is surprisingly low and glucose targets
are frequently not achieved [18]. Considering only the
postoperative period, the reduction of 1 mmol l−1 glucose
in the RABBIT 2 surgery trial with a subcutaneous basal-
bolus regimen compared to sliding scale algorithm signifi-
cantly reduced postoperative complications in patients
with DM type 2 [19]. These data also suggest that we
cannot simply tolerate glucose levels above 10 mmol l−1.
Recently, incretins have been introduced to lower
blood glucose. The main hormone of the incretin sys-
tem is glucagon-like peptide–1 (GLP-1). GLP-1 in-
creases insulin and decreases glucagon secretion in a
glucose-dependent manner, resulting in low incidence
of hypoglycaemia, which is a major advantage in the
perioperative period and may reduce workload, thereby
improving compliance. Intravenous administration of
GLP-1 after major abdominal surgery normalisedblood glucose levels, without causing hypoglycaemic
events [20].
In conclusion, DM is a relevant and prevalent disease,
which predisposes surgical patients to hyperglycaemia
and postoperative complications. Despite being one of
the most encountered co-morbidities in the operating
theatre, there is a lack of clinical trials regarding the
optimal perioperative management of elevated glucose
levels. Our primary objective is to investigate the opti-
mal intraoperative treatment algorithm to lower glucose
in patients with DM type 2 undergoing non-cardiac
surgery, comparing intraoperative GIK infusion, insulin
bolus regimen and GPL-1 (liraglutide) treatment.
Methods/Design
Ethical approval
This study protocol was approved by the medical ethical
committee of the Academic Medical Centre in Amsterdam
and by the central committee on research involving human
subjects (CCMO) acting as competent authority. The study
protocol adheres to the Declaration of Helsinki and the
guidelines of Good Clinical Practice (GCP). The study is
registered at www.clinicaltrials.gov # NCT02036372.
Trial design
The study is a multicentre open-label randomised con-
trolled trial in adult patients with DM type 2, to evaluate
the best treatment algorithm to lower glucose in the
intraoperative setting, utilizing three parallel study arms.
We will compare a glucose-insulin-potassium (GIK) in-
fusion to an insulin bolus regimen and to treatment with
the GLP-1 agonist liraglutide. The consort flow diagram
of the trial is shown in Figure 1.
Eligibility criteria
Patients with DM type 2, treated with oral glucose low-
ering tablets or a moderate dose of insulin, scheduled
for non-cardiac surgery will be eligible for inclusion.
This is also in concordance with the population studied
in the RABBIT 2 surgery trial [19], showing a reduction
in postoperative complications when lowering glucose
by 1 mmol l−1. Further inclusion and exclusion criteria
are listed below. We set a maximum of insulin dose per
day, as we do not expect clinical effect from the GLP-1
agonist treatment when patients are treated with a daily
dose of insulin >1 IU kg−1 bodyweight. Patients with a
planned postoperative stay at the intensive care unit
(ICU) will be excluded, as the participating ICU’s use a
stricter glycaemic target, compared to the wards. Consid-
ering the suggested increased risk of pancreatitis when
using GLP-1 analogues, patients with a history of acute or
chronic pancreatitis are excluded. This point is more
extensively addressed in the discussion section.
Assessed for eligibility (n= ) 
Randomised (n=315)
Excluded
• Not meeting inclusion criteria  
(n= )
• Declined to participate(n= )
• Other (n= )
GIKinfusion (n=105) 
• Receivedallocated intervention
• Did not receive allocated 
intervention (give reasons) (n=  )
Bolus regime (n=105) 
• Received allocated intervention
• Did not receive allocated 
intervention (give reasons) (n=  )
Liraglutide treatment (n=105) 
• Received allocated intervention
• Did not receive allocated 
intervention (give reasons) (n=  )
• Lost to follow-up (give reasons) 
(n=  )
• Discontinued intervention (give 
reasons) (n=  )
• Lost to follow-up (give reasons) 
(n=  )
• Discontinued intervention (give 
reasons) (n=  )
• Lost to follow-up (give reasons) 
(n=  )
• Discontinued intervention (give 
reasons) (n=  )
Analysed intention to treat (n=  )  
- Excluded from analysis (give  
reasons) (n=  )
Analysed intention to treat (n=  ) 
- Excluded from analysis (give  
reasons) (n=  )
Analysed intention to treat (n=  ) 
- Excluded from analysis (give 
reasons) (n=  )
Figure 1 Consort flow diagram of PILGRIM trial.
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 Signed informed consent
 known diabetes mellitus type 2 for >3 months
 aged 18–75 years
 scheduled for elective non-cardiac surgery
 daily insulin dosage of <1 IU kg−1 body weight
Exclusion criteria
 Oral corticosteroid use
 Treatment with long acting GLP-1 agonist or DDP-4
inhibitor
 Planned for day-care (ambulatory) surgery
 Planned ICU stay post-operatively
 Planned bowel surgery
 History of chronic pancreatitis or idiopathic acute
pancreatitis
 Impaired liver function, defined as alanine
aminotransferase (ALAT) ≥2.5 times upper normal
limit
 Impaired renal function defined as serum-creatinine
≥133 μmol l−1 for males and ≥115 μmol l−1 for females Females of child bearing potential who are pregnant,
breast-feeding or intend to become pregnant or are
not using adequate contraceptive methods (adequate
contraceptive measures as required by local law or
practice)
 Known or suspected allergy to trial product(s) or
related products
 Any condition that the local investigator feels would
interfere with trial participation or the evaluation of
results
Study outline
The patients will be recruited during a pre-assessment
visit at the anaesthesiology department, where written
and oral information will be provided to each patient.
Written informed consent will be obtained either at the
pre-assessment visit or prior to surgery. For each patient,
age, weight, length, relevant medical history and current
medication use will be recorded. During the trial,
prophylactic dexamethasone treatment for postoperative
nausea and vomiting (PONV) is not allowed, as it is un-
known to what extent dexamethasone influences glucose
in patients with DM. The anaesthetic details will be noted
Table 2 Composite endpoint minor complications
Minor Complications Definition





CDC definition [23]/leakage of the wound
requiring longer duration of hospital stay
Pancreatitis Clinical diagnosis/Elevated amylase or
lipase
Ileus Lasting more than 72 hours
Delirium Clinical diagnosis
Length of hospital stay In days
CDC = centre for disease control.
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1 hour before surgery and 4 hours after surgery using the
PONV intensity scale [21] and numeric rating scale
(NRS). Thirty days postoperatively, all patients will be
called for the assessment of postoperative complications
(Tables 1, 2 and 3) and we will review the charts of the
patients. Patients will be called at least at three different
dates and times to minimize bias due to lost to follow up.
All the data will be entered in a digital, good clinical prac-
tice (GCP) approved database. During the whole study
period, all (serious) adverse events will be recorded and
reviewed by the Principal Investigator, according to the
GCP guidelines. If it is determined that a medication re-
lated serious adverse event presents an unreasonable risk
to patients, we will terminate the study or part of the
study presenting that risk. The trial will be monitored by
an independent monitor.
Randomisation
If eligible, patients will be randomised into one of the
three study arms. The randomisation will be 1:1:1 for
each study arm, with stratification for insulin use. We
will use block randomisation with random block sizes,
ranging from 3 to 12. The randomisation will be per-
formed with a computer based randomisation application
(TENALEA Clinical Trial Data Management System). Pa-
tients and investigators are not blinded for the treatmentTable 1 Composite endpoint major complications
Major complications Definition
Death 30- day mortality of any cause
Re-admission Unplanned admission within 30 days
after discharge
ICU-admission Unplanned ICU-admission within 30 days
after discharge
Re-operation Unplanned surgical intervention within
30 days after discharge
Deep wound infection CDC definition [23]
Pneumonia CDC definition [23]
Sepsis/bacteremia CDC definition [23]
Myocardial infarction ECG changes/elevated troponine T
and/or CK-MB enzymes
Cerebrovascular event Diagnosed by CT-scan
Deep venous thrombosis Diagnosed by Doppler and treatment started
Lung embolus Diagnosed by spiral CT-scan
Stent thrombosis Requiring surgical intervention
Bleeding Requiring intervention or transfusion of RBC’s
Respiratory failure Requiring intubation/ventilator
assistance >24 hours
Renal failure Requiring dialysis
ICU = intensive care unit, CDC = centre for disease control, CXR = chest X-ray,
ECG = electrocardiogram, RBC = red blood cells.allocation. All patients randomised will be included in the
intention to treat analysis.
Study procedures/interventions
In all patients, capillary glucose will be measured
every 60 minutes, starting 30 min prior to surgery.
The target range for plasma glucose for all study arms
is 6–8 mmol l−1. An intravenous bolus of insulin will
be administered according to treatment algorithm (Table 4).
Capillary glucose will be measured using the Accu-Chek
Inform (Roche diagnostics, Indianapolis, IL, USA).
Subjects in the glucose-insulin-potassium arm (GIK)
will receive:
 The day before surgery, the evening dose of long
acting insulin will be reduced with 50%.
 On the day of surgery, the regular insulin dose, if
applicable, and the oral glucose lowering tablets will
be withheld.
 GIK infusion: 10 mmol potassium-chloride and a
calculated insulin dose are added to a 500 ml glucose
5% solution. The infusion is started 30 minutes before
surgery at 83 ml/hr. The insulin dose in the GIK








New m○ I = (PG-7)/(200/W) + 8 I = Insulin amount,
PG = glucose 30 minutes preoperative, W = body





lycaemia For which assistance was required
tic Ketoacidosis For which admission was required
g medical help Unplanned appointment with physician
or DM nurse
e in medication Change in dose or medication stopped
within 30 days of surgery
edication Additional diabetes medication started
within 30 days of surgery









4-8 mmol/l - - -
8-9 mmol/l 2 IU 4 IU 6 IU
9-10 mmol/l 3 IU 5 IU 7 IU
10-11 mmol/l 4 IU 8 IU 12 IU
11-12 mmol/l 5 IU 9 IU 13 IU
12-13 mmol/l 6 IU 12 IU 18 IU
13-14 mmol/l 7 IU 13 IU 19 IU
14-15 mmol/l 8 IU 15 IU 20 IU
15-16 mmol/l 9 IU 16 IU 21 IU
> 16 mmol/l** 10 IU 17 IU 22 IU
*If glucose is <4 mmol l−1, give 4 g glucose iv (20 ml glucose 20%) measure
again after 10 minutes and consult research physician. If glucose is <2.3 mmol l−1
give 50 g glucose iv. (100 ml glucose 50%) measure again after 10 minutes
and consult research physician. **Consult research physician. (multiply by 18
for mg dl−1).
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surgery, start 30 min prior to surgery
○ If glucose is 4–6 mmol l−1 stop infusion and
measure again in 30 minutes
○ If glucose is <4 mmol l−1, give 4 g glucose iv.
(20 ml glucose 20%),
○ measure again after 10 minutes and consult
research physician.
○ If glucose is <2.3 mmol l−1, give 50 g glucose iv.
(100 ml glucose 50%),
measure again after 10 minutes and consult
research physician.
○ If glucose is >8 mmol l−1, treat according to
algorithm.
Subjects in the insulin Bolus Regimen arm (BR) will
receive:
 The day before surgery, the evening dose of long
acting insulin will be reduced by 50%.
 On the day of surgery:
○ If patients are using mealtime and longacting
insulin/NPH: mealtime morning dose will be
withheld.
○ If patients are using only long acting insulin/NPH:
the dose of long-acting or NPH insulin will be
reduced by 50%
○ If patients are using glucose lowering tablets:
glucose lowering tablets will be withheld on the
morning of surgery. Measure glucose every 60 min, start 30 min prior to
surgery
 Adjust glucose according to treatment algorithmSubjects in the liraglutide arm (LG) will receive:
 On the day before surgery 0.6 mg liraglutide will be
administered subcutaneously (s.c.) at 17.00 hr
(5 pm). The dose of long acting and mealtime
insulin will be reduced by 50% from the start of
liraglutide treatment.
 On the day of surgery own insulin and oral glucose
lowering tablets will be withheld.
 In case of nausea graded higher than minimal, the
second gift of liraglutide will be omitted. Otherwise,
treatment will be continued with 1.2 mg liraglutide
s.c. on the morning of surgery.
 Measure glucose every 60 min, start 30 min prior to
surgery
 Adjust glucose according to treatment algorithm
Postoperatively
The assigned treatment will be continued up to 4 hours
postoperatively. The patient will stay at the recovery
room and will remain fasted. The treatment protocol will
end 4 hours postoperatively. Hereafter, glucose will be
monitored and treated according to the hospital protocol.
Laboratory measurements
HbA1c, potassium and fasting serum glucose will be
determined 1 h prior to surgery. Fasting serum glucose
and potassium will be determined 1 hour, 4 hours and
on day 1 postoperatively. When the patient has an arterial
catheter during the surgical procedure, arterial glucose
will be measured.
Postoperative complications
The occurrence of postoperative complications will be
assessed one month postoperatively. This will be deter-
mined via chart review and telephone contact. We will
use a composite endpoint of postoperative complications
derived from the RABBIT 2 surgery trial [19] and DelIT
trial [22]. The definition of major and minor complica-
tions is shown in Tables 1 and 2. We used the definition
of the centre for disease control (CDC) for the various
infectious complications [23]. The occurrence of nausea
and vomiting during hospital admission will be assessed
and scored on the NRS scale. Diabetes related complica-
tions are shown in Table 3.
Outcome measures
Our primary outcome measure is the difference in me-
dian serum glucose between the GIK, BR and LG arm
1 hour after surgery.
The secondary outcome measures are the difference
in median serum glucose between the three study
arms at 4 hours and 1 day postoperatively, the differ-
ence in the amount of insulin administered and
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betes related complications. the hourly measurements
will be used to determine the perioperative area under
the curve of the area outside the target range. In
addition, the occurrence of mild or severe hypoglycaemia
(glucose <4.0 mmol l−1 and <2.3 mmol l−1, respect-
ively), hypokalaemia (<3.5 mmol l−1) or hyperkalaemia
(>5.0 mmol l−1) is assessed. The difference in glucose
variability, described as mean absolute glucose change
(MAG), between study arms will be calculated [24].
The MAG is calculated by adding the absolute differ-
ences of the glucose values, divided by the time over
which the measurements were taken.
Statistical analyses
Sample size calculation
A 1 mmol l−1 decrease in glucose resulted in a relevant
decrease in postoperative complications (8.7 mmol l−1 ±
1.8 and 9.7 ± 2.4) in the RABBIT 2 surgery trial [10]. We
used the following formula to calculate the sample size:
SampleSize ¼ uþvð Þ
2 σ21þσ22ð Þ
μ1−μ2ð Þ2
. Assuming a power of 90%, a
significance level of 5% and a drop-out rate of 10%, we
will need 105 patients per treatment group to detect
a relevant difference of 1 mmol l−1 between treatment
groups. Thus in total, we will need 315 patients.
Analyses
Statistical analyses will be performed using SPSS version
21.0 (SPSS Inc., Chicago, IL, USA). All data will be ana-
lysed according to an intention-to-treat analysis. No
interim analysis is planned. Glucose is not normally dis-
tributed, thus the between group difference in median
glucose at 1 hour, 4 hours and 1 day postoperatively will
be tested with the Kruskal-Wallis test and post-hoc test-
ing using the Mann–Whitney U test. In case of missing
glucose at one hour, the last glucose measured during
surgery will be carried forward. Change in glucose will
be analysed using repeated measurements ANOVA, with
time as fixed effect and baseline glucose, time and the
interaction between treatments as covariates. Further-
more a per-protocol analysis will be performed next to
the intention-to-treat analysis. Finally, the between group
differences of the secondary outcomes will be tested with
the ANOVA, Kruskal-Wallis, student t, Mann–Whitney U
and the Chi-square test, where appropriate.
Discussion
Insulin infusion has been a long established regime for
the treatment of DM in the perioperative period and is
frequently combined with glucose and potassium for
safety reasons [5,25]. Moreover, a continuous infusion of
glucose might reduce peripheral insulin resistance [26].
An alternative for the GIK infusion is an intravenousinsulin bolus regime. Although no difference was seen
in perioperative glucose control in insulin naïve- and
insulin-dependent patients, an intravenous bolus regime
might be less time consuming than a GIK infusion plus
bolus regime [27,28]. GLP-1 agonists have potential ad-
vantages over established DM treatments with insulin
during the intraoperative period, due to the low risk of
hypoglycaemia. For proper execution of all regimes,
perioperative glucose measurements are mandatory.
Since the start of GLP-1 treatment, it has been sug-
gested that the use of GLP-1 agonists is associated with
an increased risk of pancreatitis [29]. However, patients
with DM type 2 and obesity, regardless of treatment,
have an increased risk of developing pancreatitis com-
pared to patients without DM [30]. A recent meta-
analysis of 55 randomized controlled trials (n = 33,350)
showed no increased risk for pancreatitis in patients
using GLP-1 agonists (OR 1.05, 95% CI 0.37 to 2.94)
[31]. Also in a large observational trial with over 20,000
new incretin users, no increased risk for pancreatitis was
found when compared to patients with DM using sulfo-
nylureas, HR 1.00, 95% CI 0.59 to 1.70 [32]. Although
these studies do not completely exclude the possibility
of a slightly elevated risk of pancreatitis when using
GLP-1 agonists, they are reassuring and an encourage-
ment for more clinical trials using these new substances.
We think that the combination of perioperative use of
GLP-1 agonists compared with more established peri-
operative treatment regimes, makes this a relevant trial
on the optimal intraoperative treatment of DM during
non-cardiac surgery.
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